Status:
TERMINATED
Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves
Lead Sponsor:
Stuart Fisk
Collaborating Sponsors:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Gilead Sciences
Conditions:
HIV Prevention
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Pre-exposure prophylaxis, or PrEP, is a relatively new HIV prevention method where individuals who are at risk for HIV but do not currently have it take a daily pill (Truvada). PrEP has been proven me...
Detailed Description
Pre-exposure prophylaxis, or PrEP, is a relatively new HIV prevention method where individuals who are at risk for HIV but do not currently have it take a daily pill (Truvada). The CDC currently recom...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- HIV- men and women, age 18 and higher, who are seeking PrEP and deemed appropriate per local site investigator following the CDC risk indication guidelines for PrEP.
- Must fit into one of the study's CDC-identified risk strata: a) IDUs and/or b) Caucasian LGBTQ or Minority LGBTQ
- Must be able to read and write English for themselves.
- Exclusion Criteria
- Same as that for PrEP initiation, e.g., existing HIV+ diagnosis or contra-indications, creatinine GFR \< 60.
- Current or previous use of PrEP.
Exclusion
Key Trial Info
Start Date :
December 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03278990
Start Date
December 19 2018
End Date
December 16 2020
Last Update
October 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Inclusion Health, Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212